- Home
- Advocacy
- Latest News and Practice Data
- FDA doesn't challenge LDT decision
The deadline has passed to appeal the court decision that nullified the FDA's oversight regulations over laboratory-developed tests (LDTs).
Why it matters: The FDA will no longer defend the LDT rules, which pathologists and labs said threatened patient access to testing.
- The CAP applauded the March 31 decision, saying that the regulation failed to target FDA oversight and would impede patient access to safe LDTs.
- The FDA had until May 30 to appeal, but no appeal was filed.
Go deeper: Read the CAP's amicus brief in the case.